Beijing Med-Pharm Corporation and Cytokine PharmaSciences, Inc. Reach Agreement to Distribute the Cervidil(R) Vaginal Insert Throughout the People's Republic of China.PLYMOUTH MEETING, Pa. & KING OF PRUSSIA King of Prussia, industrialized suburban area (1990 pop. 18,406), Montgomery co., SE Pa. It has glass and steel fabricating, food processing, printing and publishing, and varied manufacturing (textiles, liquified petroleum gas, water-treatment and electrical , Pa. -- Beijing Med-Pharm Corporation (BJGP BJGP British Journal of General Practice .PK) and Cytokine Cytokine Any of a group of soluble proteins that are released by a cell to send messages which are delivered to the same cell (autocrine), an adjacent cell (paracrine), or a distant cell (endocrine). PharmaSciences, Inc. today announced they have reached a distribution agreement whereby Beijing Med-Pharm will be responsible for the distribution of Cytokine's Cervidil(R) vaginal insert in the People's Republic of China. "We are pleased that Cytokine PharmaSciences has entrusted Cervidil to Beijing Med-Pharm," says Martyn D. Greenacre, Chairman of Beijing Med-Pharm. "This underscores the faith that top U.S. pharma companies place in Beijing Med-Pharm to generate terrific results in China." "China is one of the fastest growing pharmaceutical markets in the world," says Vidal de la Cruz de la Cruz is a common surname in the Spanish language meaning 'of The Cross.'
Cervidil is used to ripen rip·en tr. & intr.v. rip·ened, rip·en·ing, rip·ens To make or become ripe or riper; mature. See Synonyms at mature. rip the cervix in preparation for childbirth when labor is induced. It has been approved for use by the U.S. Food and Drug Administration and is marketed as Cervidil in North America, Australia, and New Zealand New Zealand (zē`lənd), island country (2005 est. pop. 4,035,000), 104,454 sq mi (270,534 sq km), in the S Pacific Ocean, over 1,000 mi (1,600 km) SE of Australia. The capital is Wellington; the largest city and leading port is Auckland. and as Propess(R) in most other parts of the world. Beijing Med-Pharm expects the product to be marketed in the People's Republic of China as Propess. About Beijing Med-Pharm Corporation Beijing Med-Pharm Corporation is a pharmaceutical marketing company that offers the following services in China through its wholly-owned subsidiary, Beijing Med-Pharm Market Calculating Co. Ltd.: pre-market entry analysis; clinical trial management; product registration; market research; and pharmaceutical marketing to physicians, hospitals and other healthcare providers. For more information, contact Ben Austin at (917) 686-3979. On the Web: www.beijingmedpharm.com About Cytokine PharmaSciences, Inc. Cytokine PharmaSciences, Inc. is a successful biopharmaceutical company located in King of Prussia, Pennsylvania For Kings of Prussia, see List of rulers of Prussia King of Prussia is an unincorporated community in Upper Merion Township, Montgomery County, Pennsylvania, United States. As of the 2000 census, its population was 18,511. (near Philadelphia), USA. The company licenses technologies from academia and other sources, develops products from those technologies and outlicenses the products to third parties for marketing. For more information, go to www.cytokinepharmasciences.com In addition to historical facts or statements of current condition, this press release contains forward-looking statements within the meaning of the "Safe Harbor Safe Harbor 1. A legal provision to reduce or eliminate liability as long as good faith is demonstrated. 2. A form of shark repellent implemented by a target company acquiring a business that is so poorly regulated that the target itself is less attractive. " provisions of The Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and of 1995 regarding the future distribution of Cervidil or Propess and Beijing Med-Pharm's expectations about the marketing of this product in the People's Republic of China. Forward-looking statements provide Beijing Med-Pharm's current expectations or forecasts of future events and could be materially different than reflected in these forward-looking statements due to various factors, including general financial, economic and political conditions affecting the biotechnology and pharmaceutical industries and the Chinese pharmaceutical market and other factors discussed in Beijing Med-Pharm's filings with the Securities and Exchange Commission. Given these risks and uncertainties, this forward-looking statement may prove to be incorrect and you should not rely on it. Beijing Med-Pharm undertakes no obligation to update publicly this forward-looking statement. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion